A Prospective Study of Efficacy and Safety of Once-Daily Saquinavir/Ritonavir plus Two Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Thai Patients

Authors:
  • PPPraphan Phanuphak
    Praphan Phanuphak
  • SUSasiwimol Ubolyam
    Sasiwimol Ubolyam
  • JSJongkol Sankote
    Jongkol Sankote
  • PPPatcharee Pongprayoon
    Patcharee Pongprayoon
  • SSSukontha Saenawat
    Sukontha Saenawat
  • SWSaijai Wicharuk
    Saijai Wicharuk
  • SNSiriporn Nonenoy
    Siriporn Nonenoy
  • NWNatnipa Wannachai
    Natnipa Wannachai
  • SCSineenart Chautrakarn
    Sineenart Chautrakarn
  • TCTheshinee Chuenyam
    Theshinee Chuenyam
  • NJNittaya Jeanpan
    Nittaya Jeanpan
  • TNThantip Nuchapong
    Thantip Nuchapong

Abstract
Objective: To assess the efficacy and safety of first-line treatment with once-daily saquinavir/ritonavir with two nucleoside reverse transcriptase inhibitors (NRTIs), as induction therapy before enrollment in a randomized trial of structured treatment interruption strategies. Design: Two-hundred antiretroviral-naive patients with CD4 + cell counts between 200–350 at screening were enrolled in this open-label 24week study. Methods: Patients were followed up every 8 weeks for CD4 + cells, HIV RNA, and clinical and laboratory toxicities. Results: Two-hundred patients were enrolled with median baseline CD4 + cell count of 267 cells/μl and HIV RNA 50 118 (4.7 log 10 ) copies/ml. After 24 weeks of treatment, 191 of 200 (96%) patients had below 400 copies/ml HIV RNA, with 177/200 (89%) below 50 copies/ml (intent to treat, missing equals failure method), with a median rise in CD4 + cell count of 122 cells/μl. There was no significant correlation between the minimum concentration of saquinavir and HIV RNA reductions at week 8 ( P=0.957) or absolute HIV RNA at week 24 ( P=0.77). Conclusion: First-line highly active antiretroviral therapy (HAART) with once-daily saquinavir/ritonavir plus two NRTIs showed strong antiviral efficacy over 24 weeks, and should be evaluated in larger prospective randomized clinical trials.

This publication has 20 references indexed in Scilit: